RXST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RXST is not a good buy right now for an impatient buyer looking for immediate upside. The stock is in a strong downtrend (bearish moving-average stack and worsening MACD), just slipped below a key support zone (~8.75), and there are no near-term news catalysts or strong proprietary buy signals to justify stepping in today. While RSI is deeply oversold (bounce potential) and options positioning is skewed bullish, the tape is still bearish and the risk of further downside toward ~8.36 support is high.
Intellectia Proprietary Trading Signals
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms a sustained downtrend. Momentum is weakening further with MACD histogram at -0.0699 and negatively expanding (bearish momentum increasing). RSI_6 at ~19.2 is deeply oversold, which can fuel short-term mean-reversion bounces, but oversold alone is not a buy trigger when MACD is still deteriorating.
Key levels: Pivot ~9.371 (major reclaim level). Near-term resistance: 9.99 then 10.38. Support: S1 ~8.749 (price 8.68 is below this, a bearish sign), next S2 ~8.364.
Pattern-based projection provided: ~50% chance of +1.25% next day, roughly flat next week (-0.02%), and stronger 1-month upside potential (+24.31%)—but the current setup suggests that upside is more likely after a confirmed base/reclaim above ~8.75–9.37 rather than immediately.
RSI is extremely oversold (~19), increasing odds of a short-term relief bounce if selling pressure fades.
Options open interest is strongly skewed to calls (bullish tilt).
Q3 gross margin improved materially to ~79.85% (+11.80% YoY), and net loss/EPS improved YoY (loss narrowing), indicating operational efficiency gains.
Analyst price targets cluster above the current price (roughly $9–$11), implying upside if growth stabilizes.
Technical trend remains decisively bearish (bearish MA stack + worsening MACD), and price is below S1 support (~8.75), raising odds of continuation down toward ~8.
No recent news/event catalyst in the last week to trigger an immediate rerating.
Latest reported quarter: 2025/Q3. Revenue declined to $30.34M (-14.09% YoY), signaling weakening top-line momentum. Profitability metrics improved: net income increased to -$9.816M (loss narrowed, +54.88% YoY improvement), EPS improved to -$0.24 (+50% YoY improvement), and gross margin rose to ~79.85% (+11.80% YoY). Overall: improving efficiency/margins, but the market will likely require a return to sustained revenue growth before rewarding the stock.
Recent Street tone is cautious/neutral with modestly higher targets:
Wall Street pros: margin improvement, valuation discount vs peers, and potential for stabilization into 2026. Cons: uncertain re-acceleration of demand and credibility of a growth turnaround after 2025 stalling. Net: cautious/neutral consensus rather than a clear buy call.
